argenx stock: New VYVGART data span myasthenia gravis and CIDP
Published on 10/06/2026 at 18:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 29, 2026, argenx SE said it would present clinical, long-term and real-world data for VYVGART and VYVGART Hytrulo at the AANEM Annual Meeting and the MGFA Scientific Session, held in Orlando from September 29 through October 2. The company also included pipeline candidates empasiprubart and adimanebart in the program, according to an argenx release published by GlobeNewswire.
Findings across myasthenia gravis
argenx reported that one-year ADAPT SERON results showed mean Myasthenia Gravis Activities of Daily Living improvements of approximately 5 points through Week 52 in generalized myasthenia gravis patients without detectable anti-AChR antibodies. A real-world analysis of more than 1,100 U.S. patients found a mean MG-ADL reduction of 4.7 points during the first three months among patients treated within one year of diagnosis, compared with 3.5 points among those treated more than three years after diagnosis. These details were included in the company’s September 29 release.
CIDP and pipeline updates
The company also cited interim ADHERE and ADHERE+ data with follow-up extending beyond five years for patients treated with VYVGART Hytrulo in CIDP. A Phase 4 switch study found that 87% of patients remained on VYVGART Hytrulo through 12 weeks after transitioning from IVIg one week after the last IVIg dose. The same disclosure covered Phase 2 ARDA+ results for empasiprubart in multifocal motor neuropathy and Phase 1b digital gait findings for adimanebart in DOK7 congenital myasthenic syndrome. The September filing by argenx SE incorporated the release into its Form 6-K, as shown in the company’s Form 6-K filing.
